D3 Bio Presents KRAS Pipeline Updates at AACR 2026; Elisrasib (D3S-001), a Next-Generation KRAS G12C Inhibitor, Shows Strong Phase 2 Efficacy Across Multiple Tumor Types
Elisrasib monotherapy demonstrates notable efficacy in three major tumor types at its recommended phase 2 dose (RP2D , 600 mg QD). Phase 2 clinical outcomes include: 2L+ KRAS G12Ci–naive NSCLC: ORR of 58.8%, mPFS of 12.2 months 2L+ colorectal cancer...
Infinitus Presents Human Evidence-Based Research Findings at FFC 2026
GUANGZHOU, China, April 30, 2026 /PRNewswire/ -- Ma Jun, Vice President and Chief Science Innovation Officer of Infinitus (China) Company Ltd., was invited to attend the Functional Food Conference 2026 (FFC 2026), held recently in Hangzhou, Zhejiang...
Minister K Shanmugam Presents AmCham CARES Awards to companies at the AmChamSG 53rd Annual General Meeting and Social Impact Fair
Annual ceremony recognizes a record number of SMEs for their CSR contributions SINGAPORE, April 27, 2026 /PRNewswire/ --The American Chamber of Commerce in Singapore (AmChamSG) marked the 10th anniversary of its Corporate and Social Action:...
Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026
- Participants achieving HBsAg loss with pegylated interferon alfa (PEG-IFNα) ± elebsiran or BRII-179 demonstrated favorable off-treatment clinical outcomes, with most HBsAg rebounds <10 IU/mL and HBV DNA rebound infrequent and not associated...
Berlin Heals Presents Positive Late Breaking Results from the CMIC-III First-In-Human Less Invasive Study
High Impact Session presented at Heart Rhythm Society's Congress in Chicago First time showing results of new Less Invasive approach Improvement in Left Ventricular Ejection Fraction (LVEF), 6 Minute Walk Test (6MWT), Quality of Life (QOL) and New...
Kia Presents Vision Meta Turismo at Milan Design Week, Redefining the Grand Tourer for the Digital Age
Vision Meta Turismo concept embodies Kia's futuristic approach to a new era of electric mobility, offering a more dynamic, engaging, and visceral driving experience Contemporary reinterpretation of three core experiences: performance driving,...
Ractigen Therapeutics Presents Positive Phase I Data for RAG-17 in SOD1-ALS at the 2026 AAN Annual Meeting, Demonstrating 81% Reduction in Neurofilament Light Chain
— Single intrathecal dose of SCAD-siRNA therapeutic RAG-17 yields favorable safety profile and profound, durable biomarker reductions — — Preliminary data from 180 mg cohort shows trends of clinical stabilization (ALSFRS-R) — — Phase II trial is now...
AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL
SAN DIEGO, April 20, 2026 /PRNewswire/ -- Abogen, a clinical-stage biotechnology company focused on RNA innovation, today announced preliminary clinical results from the first-in-human (FIH) study of ABO2203 in patients with relapsed/refractory...
Immunofoco Presents Preclinical Data for IMV102, an In Vivo CAR-T Candidate, Demonstrating Durable Tumor Control at the AACR 2026
SHANGHAI, April 20, 2026 /PRNewswire/ -- Immunofoco today announced the presentation of new preclinical data for its in vivo BCMA-targeting CAR-T candidate, IMV102, at the AACR Annual Meeting 2026. The data demonstrate that IMV102 achieved potent...
Fapon Biopharma Presents at AACR Annual Meeting 2026, Showcasing Core Technology Platforms and Advancing Pipeline
SAN DIEGO, April 20, 2026 /PRNewswire/ -- Fapon Biopharma, a clinical-stage biotech company innovating therapeutic antibodies and fusion proteins, is pleased to announce its participation in the AACR Annual Meeting 2026, taking place April 19–22,...